Non-Invasive Deep Brain Neuromodulation for Smoking Cessation
This study is testing a new way to help people quit smoking using a device called low intensity focused ultrasound (LIFU). LIFU aims to target specific areas deep in the brain linked to nicotine addiction. You would receive either active LIFU treatments or sham (inactive) LIFU treatments, two times a week for four weeks. Researchers will measure how many cigarettes you smoke per day and look at your brain activity using fMRI (functional magnetic resonance imaging) scans to see if the treatment is successful. To join, you need to be between 20 and 60 years old, have smoked for at least five years, and meet other health requirements. The study plans to enroll 100 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 100 participants, but the phase of the study is not specified.
- What's involved
- You would receive two LIFU sessions a week for four weeks. You will also have assessments at baseline, after session 1, after session 8, and at a one-week follow-up, which includes fMRI scans.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will have a one-week follow-up appointment about five weeks after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Non-Invasive Deep Brain Neuromodulation for Smoking Cessation
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Xiaoming Du, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Cigarette per day (CPD)Baseline, session 1 (about 1-2 days after baseline), session 8 (about 4 weeks after baseline), and 1-week follow up (about 5 weeks after baseline).
Cigarette per day (CPD) is measured to index smoking reduction and cessation.
- Brain connectivity as indicated by resting state functional connectivity (rsFC) value as assessed by functional magnetic resonance imaging (fMRI)session 1 (about 1-2 days after baseline) and session 8 (about 4 weeks after baseline).
The strength of rsFC from fMRI is used to represent the brain activities that are corresponding to the transcranial magnetic stimulation (TMS) effect on smoking reduction/cessation.